澤璟製藥(688266.SH):與控股子公司簽署三特異抗體新藥ZGGS001的獨家許可協議
格隆匯 8 月 16日丨澤璟製藥(688266.SH)公佈,公司於2020年8月14日與控股子公司Gensun Biopharma, Inc.(“GENSUN”)簽署《獨家許可協議》,就三特異抗體新藥ZGGS001進行合作開發並獲得在大中華區(包括中國大陸、香港、澳門和台灣)的專利獨家授權。
此次合作是基於公司此前與GENSUN簽署的相關協議和補充協議,GENSUN向公司授予四個大分子候選藥物在大中華區(包括中國大陸、香港、澳門和台灣)開發和商業化的永久、排他許可,公司有權從GENSUN的產品管線中選定四個大分子候選藥物。詳見《蘇州澤璟生物製藥股份有限公司首次公開發行股票並在科創板上市招股説明書》。
GENSUN目前在研10餘個臨牀前項目,專注於研發腫瘤免疫治療和腫瘤免疫微環境調節抗體藥物的研發。
ZGGS001是一種新穎的三特異性抗體分子,主要抑制腫瘤免疫和多條腫瘤血管生成途徑、調節腫瘤微環境。ZGGS001能同時結合並抑制三個不同靶點且無相互之間的活性及結合干擾,並顯示良好的體內腫瘤生長抑制作用。此外,ZGGS001的表達、穩定性及成藥性良好。目前,本品處於臨牀前開發階段。
公司將就此項授權許可分別向GENSUN支付如下許可費:①固定款項:於2021年12月31日之前向GENSUN支付500萬美元;②銷售分成費:公司未來亦將按照約定在相應期限內支付相應產品大中華區年淨銷售額的6%,支付直至相關專利權到期日或相關產品在大中華區的首次商業銷售起8年孰早者為止。
ZG005、ZG006和ZGGS001這三個抗體產品的佈局,每個藥物不僅具有單藥治療晚期腫瘤的潛力,未來也有希望進一步增強產品管線的佈局,研發更多的創新組合治療,提升和鞏固公司在腫瘤治療領域和免疫治療領域的行業地位。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.